<span>Labcorp announces 2022 fourth quarter and full-year results</span>
February 16, 2023

Labcorp announces 2022 fourth quarter and full-year results

Company Provides 2023 Guidance Revenue: Q4 of $3.7 billion , versus $4.1 billion last year; Full year of $14.9 billion , versus $16.1 billion last year Diluted EPS: Q4 of $0.86 , versus $5.75 last year; Full year of $13.97 , versus $24.39 last year Adjusted EPS: Q4 of $4.14 , versus $6.77 last
Read more »
January 12, 2023

Labcorp declares quarterly dividend

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 12, 2023-- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023 , to stockholders of record as
Read more »
<span>Labcorp opens new Los Angeles based laboratory</span>
December 8, 2022

Labcorp opens new Los Angeles based laboratory

New Space Will Be Three Times Larger and Increase Testing Capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 8, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in
Read more »
November 30, 2022

Statement regarding Cambodian NHP supply

The November 16, 2022, indictment filed against the Cambodian breeder and Cambodian officials does not name or reference Labcorp.  The Early Development business has multiple global suppliers and requires its vendors to meet high regulatory compliance standards.  Ex-US sites do not use Cambodian NHP supply. The business is working to procure additional supply from other sources for our US operations. US NHP studies comprise less than 2% of overall enterprise Labcorp revenue.  
Read more »